These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 7698284)

  • 1. Inhibition of cholesterol synthesis ex vivo and in vivo by fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
    Yamamoto A; Itoh S; Hoshi K; Ichihara K
    Experientia; 1995 Mar; 51(3):223-6. PubMed ID: 7698284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Species differences in the inhibiting effect of fluvastatin, a new inhibitor of HMG-CoA reductase, on cholesterol biosynthesis.
    Yamamoto A; Itoh S; Hoshi K; Ichihara K
    Res Commun Mol Pathol Pharmacol; 1994 Dec; 86(3):325-34. PubMed ID: 7712108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective inhibition of cholesterol synthesis in liver versus extrahepatic tissues by HMG-CoA reductase inhibitors.
    Parker RA; Clark RW; Sit SY; Lanier TL; Grosso RA; Wright JJ
    J Lipid Res; 1990 Jul; 31(7):1271-82. PubMed ID: 2401858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
    Koga T; Shimada Y; Kuroda M; Tsujita Y; Hasegawa K; Yamazaki M
    Biochim Biophys Acta; 1990 Jul; 1045(2):115-20. PubMed ID: 2116173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on the induction of low-density lipoprotein receptor in HepG2 cells.
    Hayashi K; Kurokawa J; Nomura S; Kuga Y; Ohkura Y; Kajiyama G
    Biochim Biophys Acta; 1993 Apr; 1167(2):223-5. PubMed ID: 8466953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens.
    Mosley ST; Kalinowski SS; Schafer BL; Tanaka RD
    J Lipid Res; 1989 Sep; 30(9):1411-20. PubMed ID: 2513368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, scavenges free radicals and inhibits lipid peroxidation in rat liver microsomes.
    Yamamoto A; Hoshi K; Ichihara K
    Eur J Pharmacol; 1998 Nov; 361(1):143-9. PubMed ID: 9851551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
    Aoki T; Nishimura H; Nakagawa S; Kojima J; Suzuki H; Tamaki T; Wada Y; Yokoo N; Sato F; Kimata H; Kitahara M; Toyoda K; Sakashita M; Saito Y
    Arzneimittelforschung; 1997 Aug; 47(8):904-9. PubMed ID: 9296275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluvastatin normalizes the decreased turnovers of glutathione and ascorbic acid in Watanabe heritable hyperlipidaemic rabbits.
    Suzumura K; Kasahara E; Ohnishi Y; Chien KC; Inoue M
    Clin Exp Pharmacol Physiol; 2000 Sep; 27(9):709-14. PubMed ID: 10972538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct effects of statins on the vascular wall.
    Corsini A; Pazzucconi F; Arnaboldi L; Pfister P; Fumagalli R; Paoletti R; Sirtori CR
    J Cardiovasc Pharmacol; 1998 May; 31(5):773-8. PubMed ID: 9593078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High dose of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, lowers plasma cholesterol levels in homozygous Watanabe-heritable hyperlipidemic rabbits.
    Kurokawa J; Hayashi K; Toyota Y; Shingu T; Shiomi M; Kajiyama G
    Biochim Biophys Acta; 1995 Oct; 1259(1):99-104. PubMed ID: 7492622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory effect of fluvastatin on ileal ulcer formation in rats induced by nonsteroidal antiinflammatory drug.
    Hagiwara M; Kataoka K; Arimochi H; Kuwahara T; Nakayama H; Ohnishi Y
    World J Gastroenterol; 2005 Feb; 11(7):1040-3. PubMed ID: 15742411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of cytochrome P450 expression by inhibitors of hydroxymethylglutaryl-coenzyme A reductase in primary cultured rat hepatocytes and in rat liver.
    Kocarek TA; Reddy AB
    Drug Metab Dispos; 1996 Nov; 24(11):1197-204. PubMed ID: 8937853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors (statins) on tissue paraoxonase 1 and plasma platelet activating factor acetylhydrolase activities.
    Bełtowski J; Wójcicka G; Jamroz A
    J Cardiovasc Pharmacol; 2004 Jan; 43(1):121-7. PubMed ID: 14668577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective effect of fluvastatin on degradation of apolipoprotein B by a radical reaction in human plasma.
    Aoki S; Ikeda K; Yamamura M; Kojo S
    Biol Pharm Bull; 2001 Feb; 24(2):123-6. PubMed ID: 11217077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue-selective inhibition of sterol synthesis in mice by pravastatin sodium after a single or repeated oral administrations.
    Koga T; Kikuchi T; Miyazaki A; Koike H
    Lipids; 1995 Aug; 30(8):775-9. PubMed ID: 7475995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: comparison with selected HMG-CoA reductase inhibitors.
    Bocan TM; Ferguson E; McNally W; Uhlendorf PD; Bak Mueller S; Dehart P; Sliskovic DR; Roth BD; Krause BR; Newton RS
    Biochim Biophys Acta; 1992 Jan; 1123(2):133-44. PubMed ID: 1739744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase.
    Corsini A; Mazzotti M; Raiteri M; Soma MR; Gabbiani G; Fumagalli R; Paoletti R
    Atherosclerosis; 1993 Jun; 101(1):117-25. PubMed ID: 8216498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antioxidative potential of fluvastatin via the inhibition of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity.
    Bandoh T; Sato EF; Mitani H; Nakashima A; Hoshi K; Inoue M
    Biol Pharm Bull; 2003 Jun; 26(6):818-22. PubMed ID: 12808293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductase.
    Shaw MK; Newton RS; Sliskovic DR; Roth BD; Ferguson E; Krause BR
    Biochem Biophys Res Commun; 1990 Jul; 170(2):726-34. PubMed ID: 2166504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.